monica-lopez-biotalk-article-image.jpg

La Petite Noiseuse Productions Co-Founder and Executive Scientific & Artistic Director Monica Lopez, Ph.D. joins BioTalk Host Rich Bendis to discuss her career path, their consulting services, science-art integration, multidisciplinary thinking and doing in healthcare, and STEM-STEAMM education for workplace challenges of the future.

Brian Darmody is responsible for developing projects, funding opportunities, and policies to support partnerships with the private sector. Previously he was the University's  Associate Vice President for Research and Development, Director of the University of Maryland Center for Applied Policy Studies, Director of State and Federal Relations in the UMD President's Office, and served in the  University's legal counsel's office. He serves on national and state boards, including Maryland Technology Council Executive Board, Fraunhofer USA, the Maryland Economic Development Association and is past President of the Association of University Research Parks.He has served on the staff for the U.S. House of Representatives, the U.S. Health Care Financing Administration Office of Attorney-Advisor, and the Maryland General Assembly. He holds an undergraduate degree from the University of Maryland and Juris Doctor from the University of Baltimore.

Listen now on iTunes Google Play , and TuneIn

darmondy-oct-2018-biotalk-article-image.jpg

In this episode of BioTalk, Rich Bendis and guest Brian Darmody discuss growth across the region, the battle for talent and the upcoming AURP International Conference hosted in College Park.

Brian Darmody is responsible for developing projects, funding opportunities, and policies to support partnerships with the private sector. Previously he was the University's  Associate Vice President for Research and Development, Director of the University of Maryland Center for Applied Policy Studies, Director of State and Federal Relations in the UMD President's Office, and served in the  University's legal counsel's office. He serves on national and state boards, including Maryland Technology Council Executive Board, Fraunhofer USA, the Maryland Economic Development Association and is past President of the Association of University Research Parks.He has served on the staff for the U.S. House of Representatives, the U.S. Health Care Financing Administration Office of Attorney-Advisor, and the Maryland General Assembly. He holds an undergraduate degree from the University of Maryland and Juris Doctor from the University of Baltimore.

Listen now on iTunes Google Play , and TuneIn

biotalk-gallagher-vabio-article-image.jpg

Jeff Gallagher, CEO of Virginia Bio sits down with BioTalk host Rich Bendis to discuss accomplishments, challenges, and initiatives in his state and the BioHealth Capital Region.

Jeff is responsible for leading the premier statewide trade group that promotes the considerable scientific and economic impact of the life sciences industry in the Commonwealth of Virginia. Prior to taking on the leadership of Virginia Bio in May 2012, Jeff was a co-founder and served as VP & General Counsel for Lyotropic Therapeutics. This small specialty pharma company used its proprietary formulation technology to create new drug products based on both NCIs and already approved API for license, further development and commercialization by mid and large pharma. Previously he practiced corporate law in Richmond, focusing on new technology company formation, international business and intellectual property transactions. He was a co-founder and longtime Chairman of the Richmond based nonprofit World Pediatric Project. He holds an A.B. in Government from Harvard, a J.D. from the University of Wisconsin Law School, and an LL.M in Public International Law from the University of Virginia School of Law. He resides with his family in the Ginter Park area of Richmond, VA.

Listen now on iTunes Google Play , and TuneIn

Dr. Bill Hearl is the Founder and Chief Executive Officer of Immunomic Therapeutics, Inc. (“ITI”).  He is an experienced and successful scientific businessman and bio-entrepreneur, having founded both ITI and formerly Capital Genomix in 2000.   Dr. Hearl has moved ITI steadily forward from an initial license agreement with the Geron Corporation in 2006 to an animal health license in 2012 and then most recently to two license deals with Astellas Pharma for the treatment of allergies, one for Japanese red cedar and a second global allergy license.  The second deal brought ITI an upfront payment of $300,000,000 and established the Company as one of the leading entities in nucleic acid research.   Dr. Hearl funded the Company by following a strategy of seeking a series of angel investment rounds which raised in aggregate over $12 million to drive the development of its allergy products.   Prior to founding ITI and Capital Genomix, he was a senior executive at Kirkegaard & Perry Labs and then held various R&D positions at Life Technologies and Pharmacia.   Dr. Hearl holds a Ph.D. in Biochemistry from the University of Tennessee (Oak Ridge & Knoxville) and holds multiple patents in the field of gene immunization.

Listen now on iTunes Google Play , and TuneIn

Matt holds a Ph.D. in Virology from Ian Mohr’s lab at NYU Langone Medical Center.  He is also an inventor on all BeneVir patents protecting T-StealthTM, the first oncolytic virus to resist both innate and adaptive immunity. Prior to BeneVir, Matt spent 8 years at Sequella, Inc., a clinical stage anti-infectives company. At Sequella, he patented and developed a molecular diagnostic and licensed it to a major clinical diagnostics company. In addition, he designed and executed clinical trials and was involved in the development of Sequella’s antibiotic pipeline from pre-clinical to clinical.

Listen now on iTunes Google Play , and TuneIn

gaines mdbio biotalk article image

Brian joined the MdBio Foundation in November 2012 after serving as Executive Director of the Washington Redskins Charitable Foundation. He has spent most of his professional career creating and working for several entrepreneurial endeavors at the intersection of the for-profit and nonprofit worlds.Brian joined the MdBio Foundation in November 2012 after serving as Executive Director of the Washington Redskins Charitable Foundation. He has spent most of his professional career creating and working for several entrepreneurial endeavors at the intersection of the for-profit and nonprofit worlds. 

In previous roles, Brian has held leadership positions with two of America’s most effective social change organizations: College Summit and KaBOOM! Brian also was the Founding Executive Director of the Joshua Venture, a national venture philanthropy fund working to launch and support innovative nonprofits. In his business career, he was the CEO and Managing Partner of a chain of Ben & Jerry’s retail outlets in the San Francisco Bay Area and served as the Western Regional Business Manager for Ben & Jerry’s Homemade, Inc. He has also helped to found several other nonprofit organizations and served as the President of the San Francisco Human Services Commission.

Listen now on iTunes Google Play , and TuneIn

In this episode of BioTalk, Jeff Galvin, CEO & Founder of American Gene Technologies (AGT) joins host Rich Bendis to discuss genetic medicines, funding strategies, company goals, and the BioHealth Capital Region. 

Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies. In 2007, he met Dr. Roscoe Brady, an accomplished research scientist at National Institute of Neurological Disorders and Stroke (NINDS) and founded American Gene Technologies with the mission to transform peoples’ lives with genetic medicines. Jeff Galvin’s current focus is to grow AGT and he expects AGT’s patented, lead candidate for an HIV Cure to enter the clinic in 2019. AGT is a gene and cell therapeutics company with a proprietary lentiviral platform targeting major diseases, including HIV, Phenylketonuria (PKU) and cancer. The company has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine. AGT’s immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers has recently been awarded four patents. In collaboration with Stanford Medical School’s Dr. Dean Felsher, this novel approach to stimulate the body’s immune system to attack solid cancer tumors is showing promising results in animal models and is expected to enter human trials in the next 24 months.

Listen now on iTunes Google Play , and TuneIn

biotalk-angela-graham-quality-biological-image.jpg

Angela Graham, President and CEO of Quality Biological, Inc. (QBI), joins BioTalk host Rich Bendis to discuss growing a business in the Life Sciences Community, her involvement in the BHCR, and recruiting top talent in this region. Angela Graham, President and CEO of Quality Biological, Inc. (QBI), joins BioTalk host Rich Bendis to discuss growing a business in the Life Sciences Community, her involvement in the BHCR, and recruiting top talent in this region.

Angela has been in this industry for decades working for Bristol-Myers Squibb, Pfizer and UCB Pharma before taking over QBI. Her background and expertise is ideally suited to lead the company’s diversification from a leading government contractor into one which also supports the diverse R&D needs of the biopharmaceutical space.

Google Play, iTunes, TuneIn and on the website.

biotalk-Rip-Ballou-gsk-image.jpg

In this new episode of BioTalk, Rip Ballou, MD, VP & Head, GSK Global Vaccines US R&D Center and BHI President & CEO Rich Bendis discuss GSK’s move to the BioHealth Capital Region, their Vaccines Portfolio/Future, and the importance of succeeding in the industry today.

W. Ripley Ballou, MD is Vice President and Head, GSK Global Vaccines U.S. R&D Center in Rockville, MD - Just outside of Washington, DC. Prior to this he was VP and Head, Clinical Research and Translational Science, Vaccine Discovery and Development at GSK Vaccines in Rixensart, Belgium. Previously he served as Deputy Director for Vaccines, Infectious Diseases Development, Global Health at the Bill & Melinda Gates Foundation. Dr. Ballou is an expert in vaccine development and has worked in this field for more than 30 years. Trained in Internal Medicine and Infectious Diseases, he began his work on vaccines at the Walter Reed Army Institute of Research where he led the team that with GlaxoSmithKline co-developed RTS,S, the world’s most advanced malaria vaccine. Dr. Ballou has numerous publications in the field of vaccine development and infectious diseases.

Listen now on iTunes Google Play , and TuneIn

BioTalk Podcast brady scheer

In this new episode of BioTalk, Matt Brady and BHI President & CEO Rich Bendis discuss topics around lab spaces in the area including, availability, shortages, and solutions to create more in the BioHealth Capital Region.In this new episode of BioTalk, Matt Brady and BHI President & CEO Rich Bendis discuss topics around lab spaces in the area including, availability, shortages, and solutions to create more in the BioHealth Capital Region.

Since joining Scheer Partners in 2003, Matt Brady has successfully completed commercial real estate transactions for more than 500,000 square feet of office, R&D and industrial space totaling close to $100 million in transaction value.

Listen now on iTunes Google Play , and TuneIn

BioTalk Podcast anderson deloitte

Margaret Anderson, Managing Director at Deloitte Consulting LLP, sits down with host Rich Bendis for this episode of BioTalk. They discuss her career path, putting patients at the center of biomedical and public health, and engaging with all sectors. Margaret Anderson is a Managing Director at Deloitte Consulting LLP focused on using strategy to make organizations, agencies, and programs stronger and more laser focused on outcomes for patients. Her career has traversed biomedical and public health policy and she’s motivated by the change she’s seen in bringing treatments and solutions for patients forward.

As used in this podcast, “Deloitte” means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of our legal structure. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Listen now on iTunes Google Play , and TuneIn

/bhcr-pt-1-biotalk-podcast.jpg

In this second part of two episodes, Rich sits down with leaders from different parts of the BHCR to talk about what they are working on, and their thoughts on the event. His guests are Todd Haim, SBIR Director, NCI SBIR Development Center at NIH, and Matthew McMahon, Director, Office of Translational Alliances and Coordination at the National Heart, Lung, and Blood Institute at NIH

Listen now on iTunes Google Play , and TuneIn

/bhcr-pt-1-biotalk-podcast.jpg

In this first part of two episodes, Rich sits down with leaders from different parts of the BHCR to talk about what they are working on, and their thoughts on the event. His guests are Jim Jackson, SVP, CSO at Emergent BioSolutions and Jim Hughes, Vice President at University of Maryland, Baltimore.

Listen now on iTunes Google Play , and TuneIn

wyskiel-biotalk-image.jpg

Christy Wyskiel, an investor, entrepreneur, and ecosystem builder, serves as Senior Advisor to President Daniels at Johns Hopkins University. She runs the group Johns Hopkins Technology Ventures, which serves as the tech transfer, corporate partnership, and start-up arm of the university. In this episode of BioTalk, Christy and Rich discuss Tech Transfer, Innovation, Investment, Partnerships, Collaborations, and other important areas that she and JHU work on every day.

Listen now on iTunes Google Play , and TuneIn

Biotalk qi image

Lily, Qi, Assistant Chief Administrative Officer – Office of Montgomery County Executive joins Rich for this episode of BioTalk. They discuss the topics like the role that MoCo plays in Economic Development, Cultural Competence in a diverse region, and her future career goals. Lily has served County Executive Ike Leggett for eight years in various capacities and led strategic initiatives including privatizing economic development functions; establishing BioHealth Innovation, Inc. to advance research commercialization; developing global partnerships; improving nighttime economy, and developing the Comprehensive Economic Strategy. Lily joined Montgomery County after serving as Vice President of Business Development and Marketing for the Washington, DC Economic Partnership and spokesperson for the DC Department of Insurance, Securities and Banking.

Listen now on iTunes Google Play , and TuneIn